{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:00Z","timestamp":1789603800976,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04447-w","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:08:33Z","timestamp":1760173713000},"page":"1369-1379","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sex differences in the onset and outcomes of immune checkpoint inhibitor-induced overt thyroid dysfunction: a retrospective study"],"prefix":"10.1007","volume":"90","author":[{"given":"Yu","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"4447_CR1","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"B.J. Schneider, J. Naidoo, B.D. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau et al., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021). https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J. Clin. Oncol."},{"key":"4447_CR2","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"J.R. Brahmer, H. Abu-Sbeih, P.A. Ascierto, J. Brufsky, L.C. Cappelli, F.B. Cortazar, D.E. Gerber, L. Hamad, E. Hansen, D.B. Johnson et al., Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother Cancer. 9, e002435 (2021). https:\/\/doi.org\/10.1136\/jitc-2021-002435","journal-title":"J. Immunother Cancer"},{"key":"4447_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop, S.M. Tolaney, Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173\u2013182 (2018). https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol."},{"key":"4447_CR4","doi-asserted-by":"publisher","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","volume":"36","author":"S Iwama","year":"2022","unstructured":"S. Iwama, T. Kobayashi, Y. Yasuda, H. Arima, Immune checkpoint inhibitor-related thyroid dysfunction. Best Pract. Res. Clin. Endocrinol. Metab. 36, 101660 (2022). https:\/\/doi.org\/10.1016\/j.beem.2022.101660","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"4447_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2213-8587(23)00005-0","volume":"11","author":"WM Wiersinga","year":"2023","unstructured":"W.M. Wiersinga, K.G. Poppe, G. Effraimidis, Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 11, 282\u2013298 (2023). https:\/\/doi.org\/10.1016\/S2213-8587(23)00005-0","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4447_CR6","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","volume":"27","author":"D Lu","year":"2022","unstructured":"D. Lu, J. Yao, G. Yuan, Y. Gao, J. Zhang, X. Guo, Immune checkpoint inhibitor-related new-onset thyroid dysfunction: a retrospective analysis using the US FDA adverse event reporting system. Oncologist. 27, e126\u2013e132 (2022). https:\/\/doi.org\/10.1093\/oncolo\/oyab043","journal-title":"Oncologist"},{"key":"4447_CR7","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","volume":"106","author":"CA Muir","year":"2021","unstructured":"C.A. Muir, R.J. Clifton-Bligh, G.V. Long, R.A. Scolyer, S.N. Lo, M.S. Carlino, V.H.M. Tsang, A.M. Menzies, Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. 106, e3704\u2013e3713 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab263","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4447_CR8","doi-asserted-by":"publisher","first-page":"113949","DOI":"10.1016\/j.ejca.2024.113949","volume":"202","author":"OJ Kennedy","year":"2024","unstructured":"O.J. Kennedy, N. Ali, R. Lee, P. Monaghan, S. Adam, T. Cooksley, P. Lorigan, Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: a retrospective study. Eur. J. Cancer. 202, 113949 (2024). https:\/\/doi.org\/10.1016\/j.ejca.2024.113949","journal-title":"Eur. J. Cancer"},{"key":"4447_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17, 389\u2013399 (2021). https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat. Rev. Endocrinol."},{"key":"4447_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12020-023-03323-9","volume":"81","author":"L Wu","year":"2023","unstructured":"L. Wu, Y. Xu, X. Wang, X. Cheng, Y. Zhang, Y. Wang, X. Fan, H. Zhao, H. Liu, X. Chai et al., Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study. Endocrine. 81, 123\u2013133 (2023). https:\/\/doi.org\/10.1007\/s12020-023-03323-9","journal-title":"Endocrine"},{"key":"4447_CR11","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1089\/thy.2018.0116","volume":"28","author":"PC Iyer","year":"2018","unstructured":"P.C. Iyer, M.E. Cabanillas, S.G. Waguespack, M.I. Hu, S. Thosani, V.R. Lavis, N.L. Busaidy, S.K. Subudhi, A. Diab, R. Dadu, Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 28, 1243\u20131251 (2018). https:\/\/doi.org\/10.1089\/thy.2018.0116","journal-title":"Thyroid"},{"key":"4447_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00262-024-03816-0","volume":"74","author":"X Li","year":"2024","unstructured":"X. Li, Z. Song, Y. Chen, J. Wu, D. Jiang, Z. Zhang, Z. Wang, R. Zhao, Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer Immunol. Immunother. 74, 2 (2024). https:\/\/doi.org\/10.1007\/s00262-024-03816-0","journal-title":"Cancer Immunol. Immunother"},{"key":"4447_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1080\/14740338.2021.1939672","volume":"20","author":"L Pala","year":"2021","unstructured":"L. Pala, F. Conforti, The effect of patient sex on the efficacy and safety of anticancer immunotherapy. Expert Opin. Drug Saf. 20, 1535\u20131544 (2021). https:\/\/doi.org\/10.1080\/14740338.2021.1939672","journal-title":"Expert Opin. Drug Saf."},{"key":"4447_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ccell.2025.02.013","volume":"43","author":"F Conforti","year":"2025","unstructured":"F. Conforti, L. Pala, Di D. Mitri, C. Catania, E. Cocorocchio, D. Laszlo, G. Ceresoli, M. Locatelli, F. Facella, De T. Pas et al., Sex hormones, the anticancer immune response, and therapeutic opportunities. Cancer Cell. 43, 343\u2013360 (2025). https:\/\/doi.org\/10.1016\/j.ccell.2025.02.013","journal-title":"Cancer Cell."},{"key":"4447_CR15","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.immuni.2023.10.008","volume":"56","author":"JP Hoffmann","year":"2023","unstructured":"J.P. Hoffmann, J.A. Liu, K. Seddu, S.L. Klein, Sex hormone signaling and regulation of immune function. Immunity. 56, 2472\u20132491 (2023). https:\/\/doi.org\/10.1016\/j.immuni.2023.10.008","journal-title":"Immunity"},{"key":"4447_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-immunol-101320-125133","volume":"40","author":"NM Wilkinson","year":"2022","unstructured":"N.M. Wilkinson, H.-C. Chen, M.G. Lechner, M.A. Su, Sex differences in immunity. Annu. Rev. Immunol. 40, 75\u201394 (2022). https:\/\/doi.org\/10.1146\/annurev-immunol-101320-125133","journal-title":"Annu. Rev. Immunol."},{"key":"4447_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","volume":"87","author":"JG Hollowell","year":"2002","unstructured":"J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T(4), and thyroid antibodies in the united States population (1988 to 1994): National health and nutrition examination survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489\u2013499 (2002). https:\/\/doi.org\/10.1210\/jcem.87.2.8182","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4447_CR18","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","volume":"108","author":"X Zhou","year":"2023","unstructured":"X. Zhou, S. Iwama, T. Kobayashi, M. Ando, H. Arima, Risk of thyroid dysfunction in PD-1 Blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J. Clin. Endocrinol. Metab. 108, e1056\u2013e1062 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad231","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4447_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/cancers17071054","volume":"17","author":"J Canzian","year":"2025","unstructured":"J. Canzian, F. Conforti, F. Jacobs, C. Benvenuti, M. Gaudio, R. Gerosa, De R. Sanctis, A. Zambelli, Sex-related differences in immunotherapy toxicities: insights into dimorphic responses. Cancers (Basel). 17, 1054 (2025). https:\/\/doi.org\/10.3390\/cancers17071054","journal-title":"Cancers (Basel)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04447-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04447-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04447-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T18:02:44Z","timestamp":1765908164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04447-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4447"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04447-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the principles of the Declaration of Helsinki (revised 2013) and was approved by the Institutional Review Board of Beijing Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Given the retrospective design and the use of de-identified data collected during routine clinical care, the requirement for informed consent was waived by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}